RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $39
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $38 to $39.
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $38 to $39.